ArticleBMC cancer2019
Proposal for a definition of "Oligometastatic disease in pancreatic cancer".
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.ESMO open · 2023Pooled it
- Clinical benefit of locoregional therapy for oligometastasis after surgery for pancreatic cancer: a single center retrospective study.BMC cancer · 2026Article
- Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer.Updates in surgery · 2026Article
- Can Machine Learning Predict Metastatic Sites in Pancreatic Ductal Adenocarcinoma? A Radiomic Analysis.Journal of imaging informatics in medicine · 2026Article
- Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection.Journal of clinical medicine · 2025Article
- Oligometastatic pancreatic cancer: current state of management and emerging therapies.The oncologist · 2025Review
- Advances in Vaccine-Based Therapies for Pancreatic Cancer.Journal of gastrointestinal cancer · 2025Review
- Article
- Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma.iGIE : innovation, investigation and insights · 2024Article
- Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer.Radiation oncology (London, England) · 2024Article
- Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.Cancer medicine · 2024Article
- Review
- Clinical benefits of pulmonary resection for lung metastases from pancreatic cancer.Langenbeck's archives of surgery · 2023Article
- Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis.ESMO gastrointestinal oncology · 2023Article
- Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.Journal of clinical medicine · 2023Review
- How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated-A Comprehensive Review.Cancers · 2023Review
- Impact of para aortic lymph node removal on survival following resection for pancreatic adenocarcinoma.BMC surgery · 2023Article
- Survival benefit of local consolidative therapy for patients with single-organ metastatic pancreatic cancer: a propensity score-matched cross-sectional study based on 17 registries.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo date, patients with metastasized pancreatic ductal adenocarcinoma (PDAC M1) are regarded as a uniform collective. We hypothesize the existence of oligometastatic disease (OMD): a state of PDAC M1 disease with better tumor biology, limited metastasis, and increased survival.
methodsData of 128 PDAC M1 patients treated at the University of Cologne between 2008 and 2018 was reviewed. Interdependence between clinical parameter was calculated using the Mann-Whitney U-Test. Survival curves were generated using the Kaplan-Meier method and analyzed using the log-rank test.
resultsEighty-one (63%) patients had metastases confined to one organ (single organ metastasis, SOG) whereas the remaining 47 (37%) showed multiple metastatic sites (multi-organ metastasis, MOG). Survival analysis revealed a median overall survival (OS) of 12.2 months for SOG vs 4.5 months for MOG (95% CI 5.7-9.8; p < 0.001). We defined limited disease by the presence of ≤4 metastases in liver or lung. Limited disease together with CA 19-9 baseline < 1000 U/ml and response or stable disease after first-line chemotherapy defined OMD. We identified 8 patients with hepatic metastases and 2 with pulmonary metastases matching all OMD criteria. This group of 10 (7.8%) had a median overall survival of 19.4 vs 7.2 months compared to the remaining patients (95% CI 5.7-9.8; p = 0.009).
conclusionWe propose a definition of oligometastatic disease in PDAC including anatomical criteria and biological criteria reflecting better tumor biology. The 10 OMD patients (7.8%) survived significantly longer and might even benefit from surgical resection in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.